Journal of steroids & hormonal science最新文献

{"title":"A Review of the Estrous Cycle and the Neuroendocrine Mechanisms in theMare","authors":"K. Satué, Gardón Jc","doi":"10.4172/2157-7536.1000115","DOIUrl":"https://doi.org/10.4172/2157-7536.1000115","url":null,"abstract":"With an understanding of basic reproductive science, veterinarians and breeders can be better positioned to achieve their goals. It is important to understand the heat or estrus cycle in order to maximize the chances of success when breeding the mare. Reproductive activity in horses is seasonally dependent, as it is primarily affected by the length of daylight. Therefore the mare has a seasonally polyestrous type of estrous cycle. This means they have breeding season in which they have multiple heat cycles, is receptive to the stallion and ovulates; and a period where they will not go into heat or anestrus. During the anestrus period, most mares show no behavioral signs of sexual receptivity and fail to develop follicles that ovulate. There are exceptions in that a small percentage of mares that do not express a seasonal pattern in that they stay both behaviorally and physiologically receptive to stallions throughout the year. During the ovulatory season, the mare is cycling, thereby exhibiting sexual receptivity to the stallion on a regular basis and is producing follicles that ovulate. The equine estrous cycle is commonly described as a combination of a follicular phase, or estrus, and a luteal phase, or diestrus. The endocrinology of the estrous cycle involves a balance between hormones produced by the pineal gland, hypothalamus, pituitary gland, ovaries, and endometrium. Growth of antral follicles in the ovary occurs in wave-like patterns, and is influenced by several factors such as stage of the estrous cycle, season, pregnancy, age, breed and the individual. In this article will describe the neuroendocrine mechanisms related to breeding seasonality, the hormonal changes that occur during the estrus cycle as well as the variations among mares in regards to the understanding the physiological mechanisms related with the estrous cycle in the mare","PeriodicalId":17132,"journal":{"name":"Journal of steroids & hormonal science","volume":"1 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2013-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82308190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemical Stability of Progesterone in Compounded Topical Preparationsusing PLO Transdermal Cream and HRT Cream Base over a 90-DayPeriod at Two Controlled Temperatures","authors":"K. Akshita, imalla, Richard F. Dudley","doi":"10.4172/2157-7536.1000114","DOIUrl":"https://doi.org/10.4172/2157-7536.1000114","url":null,"abstract":"Topical preparations containing progesterone are increasingly compounded in pharmacies, and when done so, have expiration dates of 6 months post preparation or the stated expiration date of the API, whichever comes first. Using an HPLC method developed in our lab for the separation and quantitation of progesterone, we determined the room temperature (25°C) and refrigerated (4°C) stability of compounded progesterone in proprietary PLO Transdermal CreamTM and HRT CreamTM both manufactured by Medisca Inc. over a 90 day period. Area under the curve (AUC) measurements for the 30 and 60 day analysis reveal both compounded preparations retain >95% of the stated initial potency regardless of temperature storage conditions. However, a significant decrease in stability is noted during the last 30 day study period regardless of storage temperature for both preparations (71 and 73% for HRTTM at 25°C and 4°C respectively and 69 and 71% for PLO Transdermal CreamTM 25°C and 4°C respectively). Our data suggests that compounded progesterone preparations maintain chemical stability per USP standards (± 10%) for up to 60 days in each of the tested bases, regardless of storage temperature. Due to the significant loss in chemical stability, usage beyond 60 days post-preparation is not recommended.","PeriodicalId":17132,"journal":{"name":"Journal of steroids & hormonal science","volume":"43 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2013-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84226968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endocrine Therapy for Male Breast Cancer","authors":"I. Fentiman","doi":"10.4172/2157-7536.1000112","DOIUrl":"https://doi.org/10.4172/2157-7536.1000112","url":null,"abstract":"More than 90% of male breast cancers (MBC) are estrogen receptor positive but unfortunately over 40% are either stage III or stage IV at the time of presentation. This means that for a substantial proportion of patients, endocrine therapy will be used in a palliative role in the management of MBC. Tamoxifen is the main first line agent that is given for both adjuvant treatment and control of advanced disease. Although effective it can be more toxic in men than in women so that a significant proportion of males will become non-compliant. It is important that non-adherence is recognised and whenever possible second line therapy is instituted with either aromatase inhibitors or LHRH analogues. International collaboration in randomised trials will be necessary to determine the future endocrine therapies for MBC.","PeriodicalId":17132,"journal":{"name":"Journal of steroids & hormonal science","volume":"7 12","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2013-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91418027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity, Circulating Androgens and their Precursors","authors":"M. Dušková, H. Pospíšilová, M. Hill, Ľ. Stárka","doi":"10.4172/2157-7536.1000119","DOIUrl":"https://doi.org/10.4172/2157-7536.1000119","url":null,"abstract":"Objective: The association of obesity with a lower circulating testosterone level in men is well documented. However, reports on possible changes in the androgen spectrum in obesity are rare. Methods: To investigate this phenomenon, serum sex hormone-binding globulin (SHBG), testosterone, dihydrotestosterone, androstenedione, dehydroepiandrosterone and its sulphate, 17α-hydroxypregnenolone, 17α-hydroxyprogesterone and gonadotrophins LH and FSH concentrations were measured in fasting blood samples of 224 men divided into three groups - normal (BMI=18-25, n=109, overweight (BMI 25.10-30, n=78) and obese (BMI=30.1-39, n=37). Results: A significant decrease in testosterone, dihydrotestosterone, 17α-hydroxypregnenolone, 17α-hydroxyprogesterone and SHBG with increasing body mass index was observed, whereas insignificant changes for dehydroepiandrosterone and its sulphate, androstenedione and gonadotrophins LH and FSH, were found. The ratios of corresponding pairs of steroids were in agreement with the concept that in obesity splitting of the side chain of C 21 -steroids, and 17β-hydroxysteroid dehydrogenase-reducing activity are decreased. No changes for steroid 5α-reductase or 3β-hydroxysteroid dehydrogenase (HSD3B2) were found. Conclusion: The findings demonstrate that, in men with increasing body mass index, the formation of C 19 steroids decreases from their C21 precursors and lower 17β-hydroxysteroid dehydrogenase further confines the production of testosterone and dihydrotestosterone.","PeriodicalId":17132,"journal":{"name":"Journal of steroids & hormonal science","volume":"46 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2013-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85791524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estradiol Synthesis and Metabolism and Risk of Ovarian Cancer in Older Women Taking Prescribed or Plant-derived Estrogen Supplementation","authors":"L. Gulliver","doi":"10.4172/2157-7536.S12-003","DOIUrl":"https://doi.org/10.4172/2157-7536.S12-003","url":null,"abstract":"Estradiol, the most potent of the biological estrogens, is implicated in the genesis of ovarian epithelial cancer, a heterogeneous cancer affecting mainly older women. The postmenopausal ovary traditionally has not been viewed as contributing significantly to estradiol synthesis, since this is thought to occur almost exclusively as the result of peripheral aromatization of adrenal androgens. Recent evidence supports a role for both normal and malignant ovarian tissue in de novo synthesis of estradiol using inactive biological precursors and available enzymatic pathways. The process is termed “intracrinology”. The present paper reviews available evidence for the intracrinological synthesis of estradiol in ovarian surface epithelium. It further proposes how exogenous supplementation with synthetic hormone replacement may act to augment this process by increasing the risk of developing ovarian epithelial cancer in older women. Phytoestrogens are also examined for their role in regulating levels of estradiol metabolites with potent estrogenic and carcinogenic potential.","PeriodicalId":17132,"journal":{"name":"Journal of steroids & hormonal science","volume":"59 1","pages":"0-0"},"PeriodicalIF":0.0,"publicationDate":"2013-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74152473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fluorescently-Labeled Estradiol Internalization and Membrane Trafficking in Live N-38 Neuronal Cells Visualized with Total Internal Reflection Fluorescence Microscopy.","authors":"Kassandra Kisler,&nbsp;Robert H Chow,&nbsp;Reymundo Dominguez","doi":"10.4172/2157-7536.S12-002","DOIUrl":"https://doi.org/10.4172/2157-7536.S12-002","url":null,"abstract":"<p><p>Estradiol is a steroid hormone that binds and activates estradiol receptors. Activation of these receptors is known to modulate neuronal physiology and provide neuroprotection, but it is not completely understood how estradiol mediates these actions on the nervous system. Activation of a sub-population of estradiol receptor-α (ERα), originally identified as a nuclear protein, localizes to the plasma membrane and appears to be a critical step in neuroprotection against brain injury and disease. Previously we showed that estradiol stimulates the rapid and transient trafficking of plasma membrane ERα in primary hypothalamic neurons, and internalization of membrane-impermeant estradiol (E6BSA-FITC) into cortical neuron endosomes <i>in vitro</i>. These findings support the concept that estradiol activates and down-regulates plasma membrane ERα by triggering endocytosis. Here, we use TIRFM (total internal reflection fluorescence microscopy) to image the trafficking of E6BSA-FITC, and GFP-labeled ERα, in live cells in real time. We show that activation of plasma membrane ERs by E6BSA-FITC result in internalization of the fluorescent ligand in live N-38 neurons, an immortalized hypothalamic cell line. Pretreatment with ER antagonist ICI 182,780 decreased the number of E6BSA-FITC labeled puncta observed. We also observed in live N-38 neurons that E6BSA-FITC co-localized with FM4-64 and LysoTracker fluorescent dyes that label endosomes and lysosomes. Our results provide further evidence that plasma membrane ERα activation results in endocytosis of the receptor.</p>","PeriodicalId":17132,"journal":{"name":"Journal of steroids & hormonal science","volume":"Suppl 12 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3863688/pdf/nihms493498.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31967875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treating Idiopathic Male Infertility with a Combination of TamoxifenCitrate and a Natural Compost with Antioxidant and Androgen-MimeticAction","authors":"F. Iacono, D. Prezioso, A. Ruffo, G. Dilauro, E. Illiano, G. Romeo, L. Romis","doi":"10.4172/2157-7536.S5-002","DOIUrl":"https://doi.org/10.4172/2157-7536.S5-002","url":null,"abstract":"Background: We investigated the efficacy of a combination therapy with tamoxifen citrate and a natural composite containing Tribulus terrestris, alga Ecklonia bicyclis and polymers of d-glucosamine and n-acetyl d-glucosamine in treating male idiopathic infertility. \u0000 \u0000Methods: In this prospective, randomized double blind, placebo-controlled study, we enrolled ninety infertile men at our department of urology at University Federico II of Naples. Mean age was 29.2 ± 7.8 [± SD]. Inclusion criteria consisted of the repeated exhibition of oligoasthenozoospermia (OA) without detectable cause (unexplained OA). Patients were randomly assigned to three treatment groups: Group A (n=30) receiving tamoxifene citrate (20 mg/day) and a natural composite with an antioxidant and androgen-mimetic action (150 mg of alga Ecklonia Bicyclis, 396 mg of Tribulus terrestris and 144 mg of polymers of d-glucosamine and n-acetyl d-glucosamine); Group B (n=30) receiving tamoxifene citrate (20 mg/day) and Group C receiving placebo (n=30). We evaluated the number of spontaneous pregnancies, sperm volume, concentration, sperm total motility, sperm forward progressive motility, normal sperm morphology. \u0000 \u0000Results: After 6 months of therapy the number of spontaneous pregnancies was markedly higher in the Group A (13 pregnancies, 33.3%) then the other two groups: Group B (6 pregnancies, 20%) and Group C (4 pregnancies, 13.3%). Sperm concentration improved in the Group A from a mean 8.49 × 106 cells/ml ± 5.57 at baseline to 22.1 × 106 cells/ml ± 1,63 (p ≤ 0.001). In the Group B there was an improvement from a mean 7.98 × 106 at baseline to 14.43 × 106 cells/ml ± 3,43 (p=0.002). Group C did not see a statistically significant improvement of sperm number, from a concentration of 9.65 × 106 cells/ml ± 6.54 to 10.53 × 106 cells/ml ± 8.5 (p=0.0025). In Group A, sperm total motility improved from 31% ± 11% at baseline to 40% ± 14% (p=0.007) whilst the forward progressive motility slightly improved from 5% ± 3% to 9% ± 4% (p=0.0034). In the group B and C, there were not reported statistically significant changes of motility. \u0000 \u0000Conclusions: The combination therapy with tamoxifen citrate and the natural compound with an andorgen-mimetic and antioxidant action leads to a higher incidence of pregnancy rates and gives a statistically significant improvement of semen parameters comparing with the single use of tamoxifen citrate and with the control group.","PeriodicalId":17132,"journal":{"name":"Journal of steroids & hormonal science","volume":"1996 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2013-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88139174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early vs. Delayed Hormonal Treatment in Locally Advanced orAsymptomatic Metastatic Prostatic Cancer Patient Dilemma: A Review","authors":"D. Prezioso, F. Iacono, G. Romeo, A. Ruffo, N. Russo, E. Illiano","doi":"10.4172/2157-7536.S5-001","DOIUrl":"https://doi.org/10.4172/2157-7536.S5-001","url":null,"abstract":"Introduction: Hormonal therapy for prostate cancer has been used for more than 60 years in patient. Whether immediate or deferred hormonal treatment is best for patients with locally advanced prostate cancer (LAPC) and/or or asymptomatic metastasis who are not suitable for curative local treatment of prostate cancer has been debated since its introduction. The objective of this work is to compare the effectiveness of hormonal treatment as an early or as a deferred intervention for patients with (LAPC) and/or asymptomatic metastasis. \u0000 \u0000Materials and methods: Systematic review and meta-analysis of trials published during 1950 to 2011. \u0000 \u0000Results: We retrieved 22 articles for detailed review, of which 8 met inclusion criteria. The Veterans Administration Cooperative Urological Research Group (VACURG) suggested that delaying hormonal therapy did not compromise overall survival and that many of the patients died of causes other than prostate cancer. In the European Organization for Research and Treatment of Cancer (EORTC) 30846 trial the median survival for delayed endocrine treatment was 6.1 yr and for immediate treatment 7.6 yr, the HR for survival on delayed vs immediate treatment was 1.23 (95% CI 0.88 to 1.71), indicating a 23% non significant trend in favor of early treatment. In protocol EORTC 30891 the immediate androgen deprivation resulted in a modest but statistically significant increase in overall survival but no significant difference in prostate cancer mortality or symptom-free survival. The protocol SAKK 08/88 showed for elderly, asymptomatic patients not undergoing curative local treatment, the lack of any major advantage of immediate compared with deferred hormonal treatment regarding quality of life or overall survival. \u0000 \u0000Conclusions: The early intervention with hormonal treatment for patients with LAPC provides important reductions in all-cause mortality, prostate cancer-specific mortality, overall progression, and distant progression compared with deferring their use until standard care has failed to halt the disease.","PeriodicalId":17132,"journal":{"name":"Journal of steroids & hormonal science","volume":"780 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2013-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77051555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Lipofundin® on the Measurement of Total Bilirubin by Spectrophotometry","authors":"J. Hsueh, K. Hwang, L. Pai, Y. Shih, J. Liaw, Shyi-Jou Chen, Shinn-Ying Ho, H. Fan","doi":"10.4172/2157-7536.1000118","DOIUrl":"https://doi.org/10.4172/2157-7536.1000118","url":null,"abstract":"Background: Jaundice occurs frequently in neonates and can cause severe neurological complications; hence, hyperbilirubinemia is usually monitored by direct spectrophotometry. However, lipemia, resulting from inborn disorders or parenteral feeding of preterm neonates with lipid emulsion, may interfere with certain laboratory assessments. Here, we evaluated whether artificial lipemia also interferes with bilirubin measurement by direct spectrophotometry. Methods: Total bilirubin levels were assessed by the spectrophotometry when serial concentrations of Lipofundin®, medium-chain triglycerides, or a stabilizer solution, were added to cord blood samples from five full-term and five preterm newborn infants. Results: In blood specimens from ten neonates, spectrophotometry-determined bilirubin levels proportionally and significantly increased in the presence of Lipofundin® at least 1% v/v or 10% medium-chain triglycerides at least 10% v/v in all pre-term and full-term infants. The stabilizer solution caused no interference. Conclusion: Lipofundin® in the cord blood interferes with spectrophotometric measurement of total bilirubin; this effect is mainly related to triglyceride levels and has implications for management of neonates with jaundice.","PeriodicalId":17132,"journal":{"name":"Journal of steroids & hormonal science","volume":"65 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76867019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decrease in Aryl Hydrocarbon Receptor and 17β-Estradiol Receptor (A&B) Gene Expression in The Hypothalamus and The Pineal Gland, After Administration of Dimethylbenz (A) Anthracene, A Mammary Carcinogen, To Sprague-Dawley Female Rats.","authors":"T. Cadoudal, V. Lenoir, G. Penot, I. Sathish, Yueqin Zhao, X. Coumoul, C. Forest, B. Kerdelhué","doi":"10.4172/2157-7536.1000127","DOIUrl":"https://doi.org/10.4172/2157-7536.1000127","url":null,"abstract":"Purpose: The promotion of mammary adenocarcinoma induced by Dimethyl benz (a) Anthracene (DMBA) is preceded by disruptions of the Hypothalamo-Pituitary-Gonadal and Hypothalamo-Pituitary-Adrenal axes and by a reduction of the secretion of Melatonin. We hypothesized that these disruptions might be induced by changes, in neuroendocrine structures of the brain, in the gene expression of receptors for Aryl Hydrocarbon (AHR) and 17β-Estradiol (ERS1 and ERS2). Methods: Sprague Dawley female rats received one single administration of DMBA (75 mg/kg) at 52-55 days of age and were ovariectomized 5 days later. Then, one month later, RNAs from the Pineal Gland, the Hippocampus and the Hypothalamus were prepared and analyzed by real-time PCR for the presence of the transcripts encoding receptors for AHR and 17β-Estradiol (ERS1 and ERS2) together with those encoding Gonadotropin Releasing Hormone (GNRH1),Corticotropin Releasing Hormone (CRH) and Hydroxy-Indol-O-Methyl-Transferase (ASMT),the rate limiting enzyme for the synthesis of Melatonin. Results: There was a long lasting and almost identical decrease in the expression of AHR, ERS1 and ERS2 in the Hypothalamus and the Pineal Gland. Also, there was an increase in the expression of ASMT and GNRH1 genes in the Pineal Gland, and of the GNRH1 gene in the Hypothalamus.However and, very interestingly, no effect was seen for the expression of any investigated gene in the Hippocampus, a structure of the brain implicated in cognition. Conclusion: DMBA reduces the brain expression of AHR, ERS1 and ERS2, key transcriptional factors, but only in brain structures involved in the control of neuroendocrine systems.","PeriodicalId":17132,"journal":{"name":"Journal of steroids & hormonal science","volume":"2012 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86381544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}